+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the PerQdisc Nucleus Replacement Device NRD for patients with degenerative disc disease DDD causing chronic low back pain. This prospective, open-label, multi-center study involves 72 patients who have DDD in one or more lumbar discs between L1 and S1. The study aims to collect additional data on this minimally invasive device, which is designed to maintain disc height and preserve spinal motion compared to the current standard spinal fusion surgery. Participants will undergo nucleus replacement surgery using the PerQdisc device via standard anterior, lateral, or minimally invasive posterolateral surgical approaches to replace the single nucleus pulposus in the affected lumbar disc. All surgeries require approval from a Medical Advisory Board. The study focuses on patients who have exhausted at least six months of conservative treatments for their back pain and meet specific criteria, including disc height and pain scores. During the study, participants will be monitored closely with evaluations at multiple time points up to five years. Researchers will assess performance outcomes such as disability Oswestry Disability Index, pain levels Visual Analog Scale, disc height, and range of motion, as well as safety outcomes including device expulsion, failure, neurological status, revision surgeries, and serious adverse events. Follow-up visits will include questionnaires, imaging, and clinical assessments to track the devices impact over time.

Age: 22Years +All GendersPhase Not Applicable
11 locations
P

Actively Recruiting

Researchers are evaluating ZE94-0605, an oral selective cyclin-dependent kinase 2 CDK2 inhibitor, in adults with advanced, unresectable, or metastatic solid tumors that have not responded to or are intolerant of existing therapies. This first-in-human, open-label Phase 1 study consists of two parts Phase 1a to find the highest safe dose and biologically effective dose through sequential dose escalation, and Phase 1b to randomize participants with specific molecular features such as CCNE1 amplification to determine the recommended Phase 2 dose. ZE94-0605 is given orally once daily in a fasted state in continuous 28-day cycles. Phase 1a explores doses from 50 mg optional up to 650 mg or higher if needed, while Phase 1b randomizes about 30 participants to receive either the maximum tolerated dose or one dose level below it. Treatment continues until disease progression, unacceptable side effects, withdrawal, or completion of 26 cycles. Participants will undergo regular assessments including response evaluations before dosing on several cycle days, detailed pharmacokinetic and biomarker testing during early cycles, and circulating tumor DNA analysis at multiple timepoints. Researchers will monitor safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity. The study duration may extend up to approximately 24 months with ongoing monitoring and follow-up.

Age: 18Years +All GendersPhase 1
3 locations
E

Actively Recruiting

Researchers are evaluating the safety, pharmacokinetics, pharmacodynamics, and early effects of the drug combination ZE50-0134 and Azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia AML. This open-label Phase 1b study focuses on patients who have not responded to previous treatments or whose disease has returned. The study aims to find the best dose and schedule of this combination therapy using a 3 3 dose escalation design before expanding to a larger group of patients. The study has two parts first, a dose escalation phase where different doses of Lonitoclax ZE50-0134 combined with Azacitidine are tested to find the biologically effective dose. Then, an expansion phase will enroll about 30 patients divided into two groups receiving different dose levels to determine the recommended phase 2 dose. Treatments include oral capsules of ZE50-0134 given once or twice daily and Azacitidine administered at 75 mgm2 daily for 7 days. Adjustments to doses may occur based on tolerability and safety findings. Participants will be involved in up to 24 cycles of treatment, each lasting 4 weeks. They will undergo assessments including safety monitoring and measuring responses to treatment. Researchers will evaluate how well patients blood counts recover, monitor side effects, and track event-free survival and remission duration. Close monitoring during treatment helps understand the best dosing and safety profile of the combination. The total study duration may extend up to nearly two years, including follow-up periods.

Age: 18Years +All GendersPhase 1
6 locations
G

Actively Recruiting

Researchers are conducting a Phase 3, global, randomized, open-label trial to compare the effects of brelovitug BJT-778 and bulevirtide for treating chronic hepatitis delta infection CHD. The study aims to evaluate the long-term effectiveness of brelovitug compared to bulevirtide in patients with chronic HDV infection. This trial involves approximately 172 participants assigned to different treatment arms. Participants are randomized 31 into two groups. One group receives brelovitug 300 mg by subcutaneous injection once weekly for 96 weeks. The other group receives bulevirtide 2 mg by subcutaneous injection once daily for 48 weeks, followed by brelovitug 300 mg once weekly for the next 48 weeks. This design allows comparison of both treatments and their sequences over nearly two years. Throughout the study, participants will undergo regular monitoring including blood tests to measure HDV RNA levels, liver enzyme normalization, and liver stiffness. Safety is assessed by tracking treatment-emergent adverse events and treatment discontinuations due to adverse events. Quality of life and liver disease progression are also evaluated. The primary outcome measures the percentage of participants achieving a virologic response and ALT normalization at 48 weeks, with long-term follow-up extending up to 96 weeks and beyond.

Age: 18Years - 99YearsAll GendersPhase 3
57 locations
I

Actively Recruiting

Researchers are evaluating ways to improve surgical treatment outcomes for liver echinococcosis complicated by biliary fistulas. The study aims to optimize diagnostic methods for early detection of biliary fistulas and improve surgical techniques to better eliminate these complications. This research focuses on refining both the diagnosis and treatment approaches to enhance patient recovery and reduce postoperative issues. The study involves conservative surgical treatment for liver echinococcosis where occult biliary fistulas are identified and managed by applying a U-shaped suture followed by medical cyanoacrylate glue between suture stitches on the fibrous capsule near the fistula. This method is being assessed to determine its effectiveness in managing biliary fistulas during surgery. Participants will be monitored for up to three months after surgery. Researchers will measure the incidence of bile leakage, the time it takes for biliary fistulas to close, treatment costs, and patients quality of life after surgery. Detailed postoperative data including patient condition, discharge characteristics, complications, and hospital stay duration will be collected to evaluate outcomes and recovery progress.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the safety and feasibility of the ColoSeal Intraluminal Colonic Diversion ICD System in adult patients with rectal and rectosigmoid cancer undergoing colorectal resection with an anastomosis. This device is designed to protect a damaged colon segment, such as a surgical anastomosis, leak, or perforation, from fecal contact for up to 14 days. The study consists of two prospective, multicenter, single-arm studies following identical protocols. Participants will have scheduled surgical resections using the surgeons preferred technique, including open, laparoscopic, or robotic approaches. After completing the colon anastomosis and confirming no leak, the ICD Device is inserted transanally and positioned with a delivery system. The devices anchor is placed in healthy bowel above the damaged area, then fixed externally to the skin with sutures and a collection bag attached. The device stays in place for about 10 days, followed by leak testing before removal. During the study, participants will undergo assessments including leak tests at insertion and removal, monitoring for device-related adverse events up to 90 days after the procedure, and evaluations of procedure success, device migration, anastomotic leakage, ostomy need, and successful device removal. Follow-up includes monitoring for complications and outcomes for up to three months post-procedure, ensuring participant safety and device feasibility.

Age: 18Years - 70YearsAll GendersPhase Not Applicable
3 locations
P

Actively Recruiting

Researchers are evaluating Ratutrelvir 83-0060, a drug that inhibits the main protease of SARS-CoV-2, along with Paxlovid Nirmatrelvir plus Ritonavir, to understand their safety and effectiveness in adults with mild to moderate COVID-19 who are not hospitalized. This open-label, randomized Phase 2a study aims to determine a safe and effective dose of Ratutrelvir and compare it with standard care, providing important information on how these treatments may help manage COVID-19 symptoms and recovery. Participants will be assigned to receive either Ratutrelvir or Paxlovid alongside standard care. The study is multicenter and open-label, meaning both researchers and participants know which treatment is given. The trial includes an experimental group receiving Ratutrelvir, a comparator group receiving Paxlovid, and a non-randomized group receiving Ratutrelvir. Treatment is given during the study period, and the research team monitors the drugs concentration in the blood to understand how it behaves in the body. During the 28-day study period, participants will be closely monitored for safety based on the occurrence and severity of any adverse events. The team will assess how long it takes for COVID-19 symptoms to improve and recover fully. Blood samples will be collected up to day 11 to analyze drug levels. Participants will undergo symptom evaluations regularly, and their health will be tracked throughout the study to ensure safety and gather data on treatment effects.

Age: 18Years +All GendersPhase 2
15 locations
E

Actively Recruiting

Researchers are evaluating the Allay4 Aortic Stent as an additional endovascular treatment for patients with Type B aortic dissection who are eligible for thoracic endovascular aortic repair TEVAR using stent grafts. The study focuses on patients who have already been selected for proximal TEVAR based on standard care. It aims to determine if the Allay4 Aortic Stent reduces the risk of aortic growth needing further treatment or rupture in the treated abdominal aorta within 12 months, while also assessing safety events within 30 days post-implantation. Participants will first receive a covered thoracic stent graft in the supraceliac position as part of standard treatment. Then, the investigational Allay4 Aortic Stent will be implanted inside the stent graft, extending below the celiac trunk to the end of the dissected aorta, typically down to the aortoiliac bifurcation. This procedure is done after the initial TEVAR and follows local guidelines for patient selection and device use. During the study, participants will undergo clinical and imaging assessments including CT scans to monitor aortic dimensions, device performance, and presence of complications. Researchers will track major adverse events within the first 30 days and evaluate freedom from aortic growth requiring reintervention or rupture at 12 months. Follow-up will continue up to 60 months to assess long-term outcomes such as mortality, reinterventions, and device-related issues, with regular visits and imaging studies scheduled throughout this time.

Age: 18Years +All GendersPhase Not Applicable
21 locations
C

Actively Recruiting

This research evaluates surgical methods for treating distal hypospadias, a common condition in boys where the urethral opening is on the underside of the penis. The study compares the standard graft-augmented tubularized incised plate G-TIP urethroplasty with a newer approach using fibrin-enhanced TIP F-TIP that applies the patients own platelet-rich fibrin PRF during surgery. The goal is to see if PRF reduces complications like urethrocutaneous fistula and narrowing of the urethral opening after surgery. Participants are male children aged 6 months to 7 years with primary or redo distal hypospadias and an unfavorable urethral plate. They will be randomly assigned to receive either F-TIP urethroplasty with PRF applied to the incised urethral plate or standard G-TIP urethroplasty without PRF. The PRF is prepared during surgery from the childs own blood using a specific centrifugation process and fixed in place before tubularization. After surgery, children will be monitored for complications, urinary function, and cosmetic outcomes over six months. Researchers will assess the occurrence of urethral complications, urethral narrowing, urinary flow rates, and cosmetic appearance using standardized scoring. The study is conducted at multiple centers and aims to provide clearer information on which surgical approach may improve healing and results in boys with this condition.

Age: 6Months - 84MonthsMALEPhase Not Applicable
2 locations
S

Actively Recruiting

Researchers are investigating the safety and effectiveness of the SiroMax17 drug-coated balloon catheter to treat narrowed coronary arteries in adults with coronary artery disease, including those with in-stent restenosis ISR or new lesions in small vessels. This prospective, open-label trial will enroll up to 60 subjects across multiple sites outside the United States, dividing them into ISR and de novo small vessel DNSV groups. A subgroup of ISR participants will join a pharmacokinetic study to understand the drugs elimination. Participants will receive treatment with the SiroMax sirolimus-coated balloon catheter targeting a single lesion per procedure. The ISR arm treats lesions within previously stented segments while the DNSV arm treats lesions in small vessels. All subjects undergo angiographic assessment during the procedure, and any non-target lesions may be treated with standard devices during the index procedure. The trial includes follow-up visits up to 5 years post-treatment, with additional visits for the pharmacokinetic subgroup. During the study, participants will be evaluated at hospital discharge, 30 days, 3 months, 6 months, 12 months, and annually through 5 years. Assessments include monitoring for major adverse cardiac events such as cardiac death, heart attack, and stroke, as well as target lesion failure. The pharmacokinetic subgroup will have an extra visit at 7 days. Researchers will collect data on safety and efficacy through clinical evaluations and angiographic imaging to understand device performance and patient outcomes over time.

Age: 21Years +All GendersPhase Not Applicable
2 locations

1-10 of 17

1